Intervention/Treatment: The trial focuses on Trastuzumab Deruxtecan, a drug administered subcutaneously, designed to treat metastatic solid tumors by targeting and destroying canc ...

Trastuzumab deruxtecan (5.4 mg/kg) is approved in Canada, Israel and the U.S. for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received a ...

CHICAGO — Trastuzumab deruxtecan extended PFS compared with standard chemotherapy for certain patients with pretreated breast cancer, according to findings presented at ASCO Annual Meeting.The ...

In patients with HER2-ultralow expression, trastuzumab deruxtecan reduced the risk of disease progression or death by 22% compared with chemotherapy (HR, 0.78 [95% CI, 0.50-1.21); median PFS was ...

Source Reference: Nishikawa T, et al "Trastuzumab deruxtecan for human epidermal growth factor receptor 2–expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): The STATICE Trial" J ...

SAN ANTONIO — Fam-trastuzumab deruxtecan-nxki significantly extended OS compared with ado-trastuzumab emtansine among previously treated patients with HER2-positive unresectable or metastatic ...

Reference: Harbeck N, Ciruelos E, Jerusalem G, et al. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial. Nature Medicine. 2024. doi: ...

Meric-Bernstam F, Makker V, Oaknin A, et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase 2 trial.

A study demonstrated the efficacy of trastuzumab deruxtecan (Enhertu) in patients with HER2-positive advanced or metastatic breast cancer, including those with brain metastases. Senior author ...

Trastuzumab deruxtecan (6.4 mg/kg) is also approved in several countries for the treatment of adult patients with locally advanced or metastatic HER2 positive gastric or gastroesophageal junction ...

8 May 2019 07:00 RNS Number : 2913Y AstraZeneca PLC 08 May 2019 8 May 2019 07:00 BST Trastuzumab deruxtecan demonstrated clinically-meaningful response in patients with refractory HER2-positive ...